Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.38 |
| ▸ | METAP2 | P50579 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4868502 | 1.00 | LMNA (0.39) | LMNAHPGDCTSLCTSBCTSS | |
| SCHEMBL4868500 | 1.00 | LMNA (0.39) | LMNAHPGDCTSLCTSBCTSS | |
| SCHEMBL4869615 | 1.00 | LMNA (0.39) | LMNAHPGDCTSLCTSBCTSS | |
| SCHEMBL4864631 | 0.99 | LMNA (0.40) | LMNAHPGDCTSLCTSBCTSS | |
| SCHEMBL4864635 | 0.99 | LMNA (0.40) | LMNAHPGDCTSLCTSBCTSS | |
| SCHEMBL4867764 | 0.89 | NAMPT (0.38) | LMNAHPGDNAMPTMETAP2ALDH1A1 | |
| SCHEMBL4868008 | 0.87 | LMNA (0.40) | LMNACTSLCTSBCTSSNAMPT | |
| SCHEMBL4864690 | 0.87 | LMNA (0.40) | LMNACTSLCTSBCTSSNAMPT | |
| SCHEMBL4864657 | 0.86 | METAP2 (0.39) | LMNANAMPTMETAP2ALDH1A1PKM | |
| SCHEMBL4866445 | 0.86 | METAP2 (0.39) | LMNANAMPTMETAP2ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332485-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORP (US) | 2008-02-19 | — | — | US | disclosed |
| US-20060160802-A1 | Peptide deformylase inhibitors | GLAXO GROUP LIMITED | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160802-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | LMNA 2515/4885HPGD 2537/4885CTSL 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.